[13] Leeners B, Geary N, Tobler PN, Asarian L
Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial Tesamorelin, a growth hormone-releasing factor analogue, in HIV-infected patients with excess abdominal fat Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials Pharmacokinetics, pharmacodynamics, and safety of ipamorelin, a novel ghrelin mimetic peptide, in healthy volunteers Ipamorelin, the first selective growth hormone secretagogue Growth hormone-releasing hormone in the treatment of HIV-associated lipodystrophy Eligibility & terms of sale This material is sold to qualified laboratory and research buyers for lawful research use only
This is also true for high Hcy levels [110]
Fluid Retention Inform patients that treatment with EGRIFTA WR may cause fluid retention, resulting in adverse reactions including edema, arthralgia, and carpal tunnel syndrome [see Warnings and Precautions (5.3)]
Also, CD326 is considered as a promising target for anti-cancer therapy because of being a part of the molecular network of oncogenic receptors
Mousa SA, Al Momen A, Al Sayegh F, Al Jaouni S, Nasrullah Z, Al Saeed H,
